evacetrapib Articles
EMA starts review of Merck & Co's cholesterol drug Tredaptive
24 December 2012
Discontinuation of dalcetrapib leaves Merck's anacetrapib as the front-running novel CETP inhibitor for dyslipidemia
20 September 2012
US genericization of clopidogrel will initially contract ACS market, before uptake of novel oral agents lifts sector to $2.7 billion
27 August 2012
Showing 1-3 of 3 articles
- 1
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
